Revenue GrowthThe significant increase in NSP in 4Q24 to $237 supported Shield delivering $32.2m in revenues for 2024, slightly ahead of expectations.

Bears Say

Cash Flow TimingThe timing at which Shield becomes cash flow positive may be delayed beyond 2025, with negative script growth being a concern.

Script GrowthNegative script growth in Q4 and a potentially soft 1Q25 driven by usual insurance renewals and unwind of year-end stocking is a concern.

Shield Therapeutics News

Shield Therapeutics Reports Positive Results for Ferric Maltol in Heart Failure Patients

Shield Therapeutics ( ($GB:STX) ) has issued an update. Shield Therapeutics announced positive results from the ORION-HF study,...

5d ago

Shield Therapeutics Reports Strong H1 2025 Results and Global Expansion

The latest update is out from Shield Therapeutics ( ($GB:STX) ). Shield Therapeutics reported a significant increase in...

11d ago

Shield Therapeutics Doubles ACCRUFeR® Revenues in Q2 2025

An update from Shield Therapeutics ( ($GB:STX) ) is now available. Shield Therapeutics reported a significant increase in...

1M ago

Shield Therapeutics Secures Shareholder Support at 2025 AGM

Shield Therapeutics ( ($GB:STX) ) has issued an update. Shield Therapeutics announced the successful passing of all resolutions...

3M ago

Shield Therapeutics Reports Strong 2024 Financial Growth and Global Expansion of ACCRUFeR®

An update from Shield Therapeutics ( ($GB:STX) ) is now available. Shield Therapeutics reported significant financial growth in...

4M ago

Shield Therapeutics Partners with VITAL-NET for ACCRUFeR® Launch in Japan

An update from Shield Therapeutics ( ($GB:STX) ) is now available. Shield Therapeutics has entered into an exclusive...

4M ago

Shield Therapeutics Reports Q1 2025 Revenue Growth and Strategic Progress

The latest update is out from Shield Therapeutics ( ($GB:STX) ). Shield Therapeutics reported a Q1 2025 trading...

5M ago

Shield Therapeutics Launches ACCRUFeR® in Canada to Address Iron Deficiency Anemia

Shield Therapeutics ( ($GB:STX) ) has issued an update. Shield Therapeutics plc has launched ACCRUFeR® in Canada, marking...

6M ago

Cautious Hold Rating on Shield Therapeutics Amidst Positive Financials and Prescription Growth Concerns

Analyst James Orsborne of Stifel Nicolaus maintained a Hold rating on Shield Therapeutics (STX – Research Report), boosting...

6M ago

Shield Therapeutics CEO Increases Stake, Signaling Confidence in Company’s Strategic Direction

Shield Therapeutics ( ($GB:STX) ) has issued an announcement. Shield Therapeutics announced that its Chief Executive Officer, Anders...

7M ago

STX FAQ

What was Shield Therapeutics PLC’s price range in the past 12 months?

Shield Therapeutics PLC lowest share price was 2.10p and its highest was 8.50p in the past 12 months.

What is Shield Therapeutics PLC’s market cap?

Shield Therapeutics PLC’s market cap is £72.92M.

When is Shield Therapeutics PLC’s upcoming earnings report date?

Shield Therapeutics PLC’s upcoming earnings report date is Apr 23, 2026 which is in 234 days.

How were Shield Therapeutics PLC’s earnings last quarter?

Shield Therapeutics PLC released its earnings results on Aug 21, 2025. The company reported -0.007p earnings per share for the quarter, missing the consensus estimate of N/A by -0.007p.

Is Shield Therapeutics PLC overvalued?

According to Wall Street analysts Shield Therapeutics PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Shield Therapeutics PLC pay dividends?

Shield Therapeutics PLC does not currently pay dividends.

What is Shield Therapeutics PLC’s EPS estimate?

Shield Therapeutics PLC’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Shield Therapeutics PLC have?

Shield Therapeutics PLC has 1,041,690,400 shares outstanding.

What happened to Shield Therapeutics PLC’s price movement after its last earnings report?

Shield Therapeutics PLC reported an EPS of -0.007p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.716%.

Which hedge fund is a major shareholder of Shield Therapeutics PLC?

Currently, no hedge funds are holding shares in GB:STX

Shield Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-396.71%

Trailing 12-Months

Asset Growth

22.50%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Shield Therapeutics PLC

Shield Therapeutics (STX) is a commercial-stage pharmaceutical company focused on addressing iron deficiency and related conditions through innovative therapies. The company operates primarily in the biopharmaceutical sector, developing and marketing its flagship product, Accrufer (ferric maltol), an oral iron replacement therapy designed to treat adult patients with iron deficiency anemia. Shield Therapeutics aims to provide effective, patient-friendly solutions that enhance the quality of life for individuals suffering from iron deficiency.